UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Cancer medicine (Malden, MA), 2022-01, Vol.11 (2), p.530-538

2022

Volltextzugriff (PDF)

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy

NPJ precision oncology, 2023-03, Vol.7 (1), p.34-34, Article 34

2023

Volltextzugriff (PDF)

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib

JAMA oncology, 2018-11, Vol.4 (11), p.1527

2018

Volltextzugriff (PDF)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

JTO clinical and research reports, 2023-08, Vol.4 (8), p.100546, Article 100546

2023

Volltextzugriff (PDF)

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.108-10, Article 108

2018

Volltextzugriff (PDF)

Initial Results from Mobile Low‐Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved Populations

The oncologist (Dayton, Ohio), 2020-05, Vol.25 (5), p.e777-e781

2020

Volltextzugriff (PDF)

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer

Journal of clinical oncology, 2021-04, Vol.39 (10), p.1165-1184

2021

Volltextzugriff (PDF)

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

Journal of clinical oncology, 2023-11, Vol.41 (33), p.5140-5150

2023

Volltextzugriff (PDF)

Rate of COVID‐19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome‐coronavirus 2: Analysis of the American Society of Clinical Oncology Registry

Cancer, 2023-06, Vol.129 (11), p.1752-1762

2023

Volltextzugriff (PDF)

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-type Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2024-09

2024

Volltextzugriff (PDF)

IASLC grading system predicts distant metastases for resected lung adenocarcinoma

Journal of clinical pathology, 2024-08, p.jcp-2024-209649

2024

Volltextzugriff (PDF)

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study

Clinical cancer research, 2023-08, Vol.29 (16), p.3203-3213

2023

Volltextzugriff (PDF)

Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer?

JCO oncology practice, 2023-09, Vol.19 (9), p.694-696

2023

Volltextzugriff (PDF)

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Clinical cancer research, 2021-05, Vol.27 (9), p.2400-2407

2021

Volltextzugriff (PDF)

Supportive Oncology in Lung Cancer: Program Development for Patients and Care Partners

Oncology issues, 2023-07, Vol.38 (4), p.63-72

2023

Volltextzugriff (PDF)

Efficacy and Safety Results of the Afatinib Expanded Access Program

Oncology and therapy, 2017-06, Vol.5 (1), p.103-110

2017

Volltextzugriff (PDF)

Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual

Clinical cancer research, 2016-11, Vol.22 (22), p.5397-5399

2016

Volltextzugriff (PDF)

Treatment of advanced squamous cell carcinoma of the lung: a review

Translational lung cancer research, 2015-10, Vol.4 (5), p.524-532

2015

Volltextzugriff (PDF)

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement

Journal of clinical oncology, 2019-01, Vol.37 (1), p.72-80

2019

Volltextzugriff (PDF)

Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies

Clinical lung cancer, 2024-07

2024

Volltextzugriff (PDF)

Targeted Therapy for Mutation-Driven Metastatic Non-Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors

Oncology (Williston Park, N.Y.), 2019-04, Vol.33 (4), p.152-155

2019

Volltextzugriff (PDF)

Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy

Cancers, 2024-07, Vol.16 (13), p.2475

2024

Volltextzugriff (PDF)

The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review

Translational cancer research, 2021-05, Vol.10 (5), p.2596-2608

2021

Volltextzugriff (PDF)

Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer

Translational lung cancer research, 2022-12, Vol.11 (12), p.2464-2476

2022

Volltextzugriff (PDF)

Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial

Practical Radiation Oncology, 2023-11, Vol.13 (6), p.531-539

2023

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(39)
Buchkapitel
(2)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Oncology
(25)
Humans
(11)
Immunotherapy
(6)
Lung Cancer
(6)
Mutation
(5)
Respiratory System
(5)
Cancer Therapies
(4)
Chemotherapy
(4)
Lung Neoplasms - Drug Therapy
(4)
Patients
(4)
Tumors
(4)
Biomarkers
(3)
Cancer
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)
Carcinoma, Non-Small-Cell Lung - Pathology
(3)
Clinical Trials As Topic - Methods
(3)
Epidermal Growth Factor Receptor
(3)
Lung Neoplasms - Pathology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement

Initial Results from Mobile Low‐Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved Populations

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

Rate of COVID‐19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome‐coronavirus 2: Analysis of the American Society of Clinical Oncology Registry

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-type Non-Small Cell Lung Cancer

IASLC grading system predicts distant metastases for resected lung adenocarcinoma

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study

Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer?

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Supportive Oncology in Lung Cancer: Program Development for Patients and Care Partners

Efficacy and Safety Results of the Afatinib Expanded Access Program

Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual

Treatment of advanced squamous cell carcinoma of the lung: a review

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement

Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies

Targeted Therapy for Mutation-Driven Metastatic Non-Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors

Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy

The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review

Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer

Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial

Suchergebnisse filtern